Tsai J F, Jeng J E, Ho M S, Chang W Y, Hsieh M Y, Lin Z Y, Tsai J H
Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
Br J Cancer. 1997;76(7):968-74. doi: 10.1038/bjc.1997.493.
To assess whether there is an additive effect between chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on the development of hepatocellular carcinoma (HCC), 400 consecutive cirrhotic patients were followed prospectively with periodic abdominal ultrasound examination and measurement of serum alpha-fetoprotein (AFP) level every 4 months. During a follow-up of 1185 person-years, 80 (20%) patients developed HCC, with an annual incidence of 6.8%. The annual incidence was 2.0% in patients negative for hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV), 6.6% in patients with HBsAg alone, 7.0% in patients with anti-HCV alone and 13.3% in patients co-infected with HBV and HCV. There was a positive linear trend in the annual incidence of HCC among patients without either marker, patients with single viral infection and patients with dual viral infection (P[for trend] < 0.0001). Cox's proportional hazard model indicated that HCV/HBV co-infection [hazard ratio (HR), 6.41; 95% confidence interval (CI), 1.80-22.80], anti-HCV alone (HR, 3.74; 95% CI, 1.07-13.07) and HBsAg alone (HR, 4.06; 95% CI, 1.23-13.34) were independently risk factors of HCC. In conclusion, there is an additive and independent effect modification of HCV and HBV infection on HCC development.
为评估慢性乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染在肝细胞癌(HCC)发生过程中是否存在叠加效应,对400例连续性肝硬化患者进行前瞻性随访,每隔4个月进行定期腹部超声检查并检测血清甲胎蛋白(AFP)水平。在1185人年的随访期间,80例(20%)患者发生了HCC,年发病率为6.8%。乙型肝炎表面抗原(HBsAg)和抗HCV抗体均为阴性的患者年发病率为2.0%,仅HBsAg阳性的患者为6.6%,仅抗HCV阳性的患者为7.0%,HBV和HCV合并感染的患者为13.3%。在无任何标志物的患者、单一病毒感染患者和双重病毒感染患者中,HCC的年发病率呈正线性趋势(趋势检验P<0.0001)。Cox比例风险模型表明,HCV/HBV合并感染(风险比[HR],6.41;95%置信区间[CI],1.80 - 22.80)、仅抗HCV阳性(HR,3.74;95%CI,1.07 - 13.07)和仅HBsAg阳性(HR,4.06;95%CI,1.23 - 13.34)是HCC的独立危险因素。总之,HCV和HBV感染在HCC发生过程中存在叠加且独立的效应修饰作用。